rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Semaglutide and Bile Duct Cancer: Pharmacovigilance Signal Analysis from FAERS

RPEP-154182026Kaur, Rimple Jeet; Gomaz, Simi Bridjit; Shaurya, Rekha; Aggarwal, Pravesh; Porchezhian, Pradakshna; Dhingra, Sameer; Sidhu, Preeti; Ambwani, Sneha; Charan, Jaykaran
evidence
The takeaway

Disproportionality analysis of FAERS data detected a pharmacovigilance signal for semaglutide-associated bile duct cancer, warranting further investigation though causation cannot be established.

Signal detected, not proven

A rare bile duct cancer signal was detected for semaglutide in the FAERS database — requires investigation but does not prove the drug causes cancer

What the researchers found

Disproportionality signal detected for semaglutide-associated bile duct cancer in FAERS database, warranting further investigation while causation remains unestablished.

Why it matters

Bile duct cancer is rare but deadly. Even a small signal from millions of users warrants careful evaluation.

How the study worked

Disproportionality analysis of FAERS database for semaglutide-associated bile duct cancer reports using proportional reporting and information component measures.

What this study cannot tell us

FAERS disproportionality signals have high false-positive rates. Cannot prove causation. Confounding by indication (diabetes/obesity increase cancer risk).

How to read the evidence

FAERS disproportionality analysis. Signal detection, not causal evidence.

When this study was published

Published in 2025.

The bigger picture

Post-marketing surveillance is essential for widely used drugs. Detecting rare cancer signals requires massive datasets like FAERS.

Questions still open

  • Is the signal confirmed in other pharmacovigilance databases?
  • Does diabetes or obesity alone explain the bile duct cancer association?
  • Should semaglutide users receive bile duct cancer screening?

Common questions

Does semaglutide cause bile duct cancer?
A pharmacovigilance signal was detected, meaning more reports than expected — but this does NOT prove causation. Diabetes and obesity themselves increase cancer risk, which could explain the signal.
Should I stop semaglutide because of this?
No. This is a signal requiring investigation, not a proven risk. The benefits of semaglutide far outweigh this unconfirmed signal. Report any unusual symptoms to your doctor.

Read the original research

Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology

View on PubMed ↗Publisher’s paper ↗

Citation

Kaur, Rimple Jeet; Gomaz, Simi Bridjit; Shaurya, Rekha; Aggarwal, Pravesh; Porchezhian, Pradakshna; Dhingra, Sameer; Sidhu, Preeti; Ambwani, Sneha; Charan, Jaykaran. (2026). Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study.. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. https://doi.org/10.1007/s12664-025-01891-4